statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioAtla, Inc. (NASDAQ:BCAB - Free Report) - Investment analysts at HC Wainwright issued their FY2028 earnings estimates for BioAtla in a research report issued to clients and investors on...

Analysts Set Expectations for BioAtla, Inc.'s FY2028 Earnings (NASDAQ:BCAB)

BioAtla (NASDAQ:BCAB - Free Report) had its price objective lowered by HC Wainwright from $10.00 to $7.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a buy rating...

BioAtla (NASDAQ:BCAB) PT Lowered to $7.00

BioAtla (NASDAQ:BCAB - Get Free Report)s stock had its "market outperform" rating restated by analysts at JMP Securities in a report issued on Thursday, Benzinga reports. They presently have a...

BioAtla (NASDAQ:BCAB) Stock Rating Reaffirmed by JMP Securities

BioAtla (NASDAQ:BCAB  Get Free Report) had its target price reduced by equities researchers at HC Wainwright from $10.00 to $7.00 in a research report issued on Wednesday, Benzinga reports...

This is a signal that BCAB's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

BioAtla (BCAB, $3.46) RSI Indicator left the overbought zone on March 27, 2024

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioAtla (BCAB Research Report) and Crinetics Pharmaceuticals...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Q4 2023 Bioatla Inc Earnings Call Transcript

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript...

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Highlights Clinical Progress Amidst Net Loss Consistent with Analyst ProjectionsRelated Stocks: BCAB...

BioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

BioAtla reports Q4 revenue $7.8M vs $5.8M last year

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Volume	398,980.00
52-Wk High	$4.07
52-Wk Low	$1.24

BCAB BioAtla Inc

About

Feed

News

Sentiment

Earnings

Fundamentals